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 Abstract 
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease 
characterized by the progressive and irreversible destruction of joints. 
RA remains an incurable condition, although a new class of drugs, biologicals, have 
made a major breakthrough in targeting and/or eliminating the immune cells, 
including T cells, B cells and monocytes/macrophages from the joints. That we 
cannot (yet?) cure the disease is most likely due to the lack of therapeutic targeting 
the endogenously activated RA synovial fibroblasts (RASF).  
Most interestingly, RASF express Toll-like receptors 1-6 rendering them prone to 
activation by exogenous and endogenous TLR ligands and resulting in the production 
of numerous powerful chemokines and cytokines. These factors are responsible for 
the repopulation of immune cells in the joints after ceasing cell depleting therapies. 
To characterize the molecular mechanisms of synovial activation, a new approach 
studying the epigenetic characteristics of RASF has been recently undertaken. 
Thereby, the pattern of histone acetylation, DNA methylation and gene expression 
regulating microRNA are being explored. 
Since auto-antibodies have the most predictive and diagnostic value for RA, it is 
challenging to study more comprehensively the contribution of auto-antibodies to the 
disease. A new screening technique, serological analysis of recombinant human 
cDNA expression library (SEREX), adapted from cancer research allowed for the 
identification of novel auto-antibodies in RA, including anti-serpin E2 auto-antibodies. 
The serpin E2 auto-antibodies were found to inhibit the activity of serpin E2 and have 
potentially a functional role in the disease. The recent findings in the field of innate 
immunity, epigenetics and autoimmunity related to the pathogenesis of RA are in the 




Rheumatoid arthritis is a chronic autoimmune disease of which the main 
characteristic is irreversible joint destruction (Harris et al., 1970). Even though it is 
known that persistent activation of the immune system in RA leads to autoimmunity, 
the trigger activating the immune response remains unclear (Goronzy and Weyand, 
2005). Before the turn of the century it was taken as a fact from clinical studies that 
nonsteroidal anti-inflammatory drugs as well as disease modifying anti-rheumatic 
drugs (DMARDS) did not result in long-term effectiveness in patients with RA. Most 
patients still suffered from functional decline, radiographic progression, work disability 
and premature mortality. Now, biological-response modifiers including recombinant 
inhibitors of TNFα (infliximab, etanercept, adalimumab), IL-1 (anakinra), T cell co-
stimulation (abatacept) and B cell targeted antibodies (rituximab) are powerful drugs 
for the majority of patients. However, since not all patients respond to these therapies 
and the disease cannot be cured yet, research has focused on the cells at the site of 
joint destruction. More attention is now paid, for example, on targeting the bone 
resorbing osteoclasts (Bull et al., 2008; Herman et al., 2008). Surprisingly, no interest 
was raised so far on the notion that, next to the development of autoimmunity and 
activation of the cytokine driven pathway of joint destruction, a cytokine-independent 
pathway driven by intrinsically activated RASF is another important part in the 
pathogenesis of RA (Gay et al., 1993; Ospelt et al., 2004). In this review we focus on 
the stimulating work done in the past years on innate immunity, epigenetic 
modulations in synovial cells and autoimmunity in RA. These new results should be 
inspiring for the development of innovative strategies in the treatment of RA. 
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2. Innate immunity 
Unlike adaptive immunity, innate immunity has a role in non-specific recognition of 
pathogens. The innate immune system constitutes the first defence against microbial 
particles such as viruses or bacteria, by which it is activated via pathogen associated 
molecular patterns (PAMPs) ligating to pattern recognition receptors (PRRs). 
Activation might also occur by other stress factors such as heat, fractures, necrosis, 
apoptosis, hypoxia or carcinogenesis via diverse molecules expressed on stressed, 
injured, infected, or transformed human cells that also act as PAMPs (Hietbrink et al., 
2006; Rius et al., 2008; Wallin et al., 2002). The role of innate immunity in the 
organism is the identification of foreign substances and their removal by 
phagocytosis or nitric oxide (NO) production and the recruitment of immune cells to 
sites of infection or inflammation by producing cytokines. Thereby, activation of the 
complement cascade and the adaptive immune system by antigen presentation 
results in the inflammatory response. We summarize here what is currently known 
about PRRs and the possible ligands to shed more light on the pathogenesis of RA 
and on possible targets for novel therapies. 
 
2.1. Toll-like receptors (TLR) in RA 
In our body, the cells of the innate immune system are equipped with PRRs to be 
ready for an immediate response to an offensive event. In this regard, it is interesting 
that synovial fibroblasts, especially when derived from RA and other inflammatory 
conditions, express on their surface a range of TLRs belonging to the group of 
membrane associated PRRs. These cells have therefore the ability to react 
immediately or within few hours to a wide range of appearing pathogens but also to 
react to interactions with human cells expressing TLR ligands and induce an immune 
response. Since RASF express increased levels of TLR2, 3 and 4, they are more 
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prone to activation by diverse TLR ligands when compared with osteoarthritis (OA) 
SF (Brentano et al., 2005b; Kim et al., 2007).  
TLR1 mainly signals in a complex with TLR2 (Takeuchi et al., 2002). This complex 
recognizes tri-acetylated lipopeptides. TLR1 has also been found to heterodimerize 
with TLR10 (Hasan et al., 2005). The ligand of this complex is however not yet 
known. TLR1 is expressed in leukocytes and in non-immune cells such as astrocytes, 
fibroblasts, keratinocytes, endothelial  and epithelial cells (Ospelt and Gay, 2008b). It 
was found to be expressed also by synovial fibroblasts, including RASF (Ospelt et al., 
2008). 
TLR2 has been identified to bind Gram-positive bacterial cell wall proteins, such as 
peptidoglycans (PGN) and bacterial lipopeptides (Brightbill et al., 1999; Underhill et 
al., 1999). Most importantly, TLR2 has been reported to be present at higher levels in 
RASF than in OASF as well as in CD14+ macrophages from RA joints when 
compared to controls, like in vitro differentiated macrophages or peripheral blood 
monocytes from the same patients (Huang et al., 2007; Kim et al., 2007). Stimulation 
of TLR2 in RASF up regulates the production of pro-inflammatory cytokines IL-6 and 
IL-15, chemokines, as well as matrix degrading metalloproteinases (MMP) and 
adhesion molecules (Jung et al., 2007; Kyburz et al., 2003; Pierer et al., 2004).  Both 
of the ligands for TLR2 and 4 induce the production of RANKL by RASF and 
subsequent osteoclastogenesis (Kim et al., 2007). The heat shock proteins Hsp60, 
Hsp70, Gp96 and high mobility group box 1 protein (HMGB1) function as host 
derived ligands for TLR2 and have been described to play a role in the pathogenesis 
of RA (Prakken et al., 1997; van Beijnum et al., 2008). Moreover, HMGB1, in contrast 
to heat shock proteins, was already described to stimulate the TLR pathways in RA 
(van Beijnum et al., 2008). 
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TLR3 is a receptor for single stranded RNA. This receptor is expressed in the 
endosome membrane and is the only known TLR that acts independently from the 
MyD88 signalling pathway. Brentano et al. in our group found TLR3 to be at higher 
levels in RA synovial tissues then in OA (2005b). TLR3 was present mainly in the 
synovial fibroblasts of the lining layer and stimulation of TLR3 signalling in RASF was 
shown to induce the expression of IFN-β, CXCL-10, CCL-5, and IL-6. Most 
interestingly, necrotic cells from synovial fluid delivered unidentified ligand binding 
and stimulating TLR3, subsequently leading to the production of the aforementioned 
pro-inflammatory cytokines. Furthermore, during acute inflammatory events, TLR3 
was shown to serve as an endogenous sensor of necrosis and to play a role as a 
regulator of the amplification of immune response (Cavassani et al., 2008). 
Another TLR over-expressed by RASF is TLR4. TLR4 is present on the surface of 
cells and binds lipopolysaccharides (LPS), a component of the outer membrane of 
gram-negative bacteria. Several endogenous host ligands binding TLR4 were 
identified. Among them was fibrinogen, fibronectin extra domain A, hyaluronan, 
HMGB1 and several heat shock proteins (Brentano et al., 2005a). Even though heat 
shock proteins, fibrinogen and hyaluronan have not yet been demonstrated to play a 
functional role as a ligand for TLR4 in RA, they are present in the synovial fluid in RA 
patients and await investigation whether they stimulate TLR4 signalling. It has been 
reported that the TLR4 pathway was activated by incubation of CHO/CD14/HuTLR-4 
reporter cells with synovial fluids and sera of RA patients (Roelofs et al., 2005). In our 
laboratory Sanchez-Pernaute et al. could show that fibrin stimulates the expression of 
proinflammatory cytokines in RASF via TLR4 (2007). Since fibrin clots are abundantly 
present in the synovium of patients with RA and free fragments of fibrin appear in the 
synovial fluid (Gormsen et al., 1971; Sanchez-Pernaute et al., 2003), fibrin could 
contribute to the stimulation of RASF via the induction of the TLR4 pathway. 
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Furthermore, citrullinated fibrin found in RA synovial tissues could possibly signal in a 
similar manner. 
TLR5 is a receptor for flagellin, the major structural protein of the flagella of gram-
negative bacteria. TLR5 is expressed mainly on monocytes and T cells. 
Nevertheless, on synovial fibroblasts, including RASF low levels of TLR5 were 
detected (Ospelt et al., 2008). TLR5 expressed on the surface of RASF was shown to 
be functional since stimulation of RASF with flagellin resulted in the induction of the 
proinflammatory cytokine IL-6. 
TLR6 forms heterodimers with TLR2 and this complex is a receptor for di-acetylated 
lipopeptides. TLR6 is expressed on monocytes, macrophages, B cells, T cells, DCs, 
PMN, NK cells as well as on non-immune cells. It was also found to be expressed in 
synovial fibroblasts, including RASF (Ospelt et al., 2008). 
Similarly to TLR3, also TLR7 has been found at higher levels in the RA synovium 
comparing to OA or healthy synovial tissues (Roelofs et al., 2005). Since RNA acts 
as a TLR7 ligand, it has been demonstrated that B cells are activated by RNA and 
RNA-associated autoantigens via the synergistic stimulation of B cell antigen 
receptor and the TLR 7 (Lau et al., 2005).  
TLR9 is localized in the endoplasmic reticulum and detects internalized microbial 
DNA with unmethylated CpG motifs and stimulates B cell activation, proliferation, and 
the production of IFN-α and IgM. Moreover, TLR9 is expressed by plasmacytoid DCs 
and B cells. Even though this receptor has not been detected on RASF it has been 
shown to play a certain role in the pathogenesis of RA. Namely, TLR9 participates in 
the stimulation of rheumatoid factor (RF) producing B cells since it acts synergistically 
with the B cell receptor (Chaturvedi et al., 2008). It has also been reported that the 
stimulation of TLR9 by microbial nonmethylated CpGs in combination with the B cell 
receptor leads to a class switch from IgM to more pathogenic IgG (He et al., 2004). 
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Interestingly, it has been demonstrated that ribosomal DNA (rDNA) containing 
hypomethylated DNA released from host derived dead cells is present at increased 
levels in the RA serum (Veiko et al., 2006). This rDNA fragments are thought to 
stimulate TLR9 signalling. Since Karouzakis in our group could show that the global 
methylation is reduced in RA synovial tissues and isolated RASF (2007), it is also 
possible that hypomethylated endogenous DNA derived from apoptotic cells could 
bind to TLR9 and the innate immune system would recognize hypomethylated host 
DNA as pathogenic. DNA hypomethylation is known to be essential for apoptotic 
DNA to induce systemic lupus erythematosus (SLE)-like autoimmune disease in 
SLE-non-susceptible mice (Wen et al., 2007). Interestingly, it has been reported that 
RF+ B cells respond to IgG2a immune complexes that contain DNA, but not to 
monomeric IgG2a antibodies alone (Leadbetter et al., 2002). 
The expression of TLR on RASF can also be induced by pro-inflammatory cytokines, 
heat shock or hypoxia (Seibl et al., 2003). Consequently, activated RASF produce 
NO which could affect the surrounding tissue (Yao et al., 2005). Activated RASF and 
macrophages also produce tissue degrading enzymes, like MMP-1, -2, -13 and -14, 
proinflammatory chemokines, like GCP-2, RANTES, MCP-1 and 2, CXCL-16 and 
cytokines including TNFα, IL-6 and IL-8, that recruit immune cells into the synovium. 
Moreover, RASF promote invasion of immune cells by expressing adhesion 
molecules such as VCAM-1 and ICAM-1. Thereby, activated RASF support 
consistently the survival of immune cells by constituting a favourable milieu for 
producing pro-inflammatory cytokines, antiapoptotic proteins and growth factors 
(Kyburz et al., 2003; Pierer et al., 2004). Taken these results together, it can be 
concluded that inhibition of TLR signalling could be an attractive approach for therapy 
in RA. On the other hand, inhibition of TLR signalling may also compromise the 
immune response against dangerous infections. 
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 2.2. Shared epitopes as part of innate immunity 
Recently an interesting article was published presenting a novel concept considering 
the shared epitope, where it was reported to act as an endogenous ligand stimulating 
the innate immunity response (Ling et al., 2007). The shared epitope has long been 
known to be associated with the occurrence of RA (de Vries-Bouwstra et al., 2008). 
Therefore, it has been speculated that a molecular mimicry between a pathogen and 
HLA-DRβ plays a role in the pathogenesis of RA (Traherne, 2008). Thereby, the T 
cells were also suggested to recognize a specific self peptide bound to HLA-DRβ and 
trigger an autoimmune response. However, no single specific peptide has ever been 
identified.  Ling at al (2007) have now shown that the shared epitope binds to cell 
surface calreticulin and subsequently triggers the innate immune response such as 
the production of NO. In individuals positive for HLA-DRβ smoking significantly 
increases the risk of developing RA (Klareskog et al., 2006). On the other hand 
smoking might induce ligands to trigger TLR signalling (Ospelt and Gay, 2008b). In 
conclusion, the latest research proving the involvement of the innate immune system 
into the pathogenesis of RA contributes to a better understanding of the initiation of 




The term epigenetics defines modifications in the genome, inheritable over cell 
generations but not involving the base pair sequence of the DNA. Epigenetic 
modulations include DNA methylation and histone modifications such as acetylation, 
methylation, phosphorylation, ribosylation, ubiquitination and sumoylation (Figure 1).  
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So far several epigenetic abnormalities have been described in cancer cells. Recent 
studies on epigenetics, including DNA methylation and modulations of histone 
acetylation have also contributed to a better understanding of the pathogenesis of 
RA. The first report on aberrations in the epigenetic code in RA was published 
already in 1990 (Richardson et al.). The authors showed that the DNA in T cells of 
RA patients is hypomethylated. Few years later, we have shown that RASF are 
intrinsically activated and resemble tumor-like cells in some aspects (Muller-Ladner 
et al., 1996). Activation of synovial cells leads to an increased production of powerful 
proinflammatory cytokines that in turn attract more inflammatory cells to the joints 
(Ospelt and Gay, 2008a). RASF produce also increased levels matrix degrading 
enzymes as well as adhesion molecules. Moreover, RASF have intrinsically high 
levels of small ubiquitin modifier 1 (SUMO-1) which contributes to their resistance to 
apoptosis (Meinecke et al., 2007). RASF also have increased levels of expression of 
proto-oncogenes and cell cycle proteins suggesting transformation (Davis, 2003). 
However, since RASF do not proliferate extensively we prefer to refer to them as 
cells with activated phenotype (Ospelt and Gay, 2008a). It needs to be shown in the 




3.1. DNA methylation in RA 
DNA methylation in gene promoters containing CpG islands takes place on cytosines 
of the CpGs, and is connected to a decreased transcription of genes, since 
transcription factors generally can not bind to promoters containing methylated CpG 
islands. In this manner genes in heterochromatin are silenced.  
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Recent investigations in our group have shown that RASF have decreased levels of 
global DNA methylation (Karouzakis et al., 2007), which leads to an increased 
expression of cell activating genes and might stimulate the innate immune response 
via TLR9. We reported further that the transcription of the retrotransposable element 
LINE-1 is reactivated in RASF due to hypomethylation of CpG islands in its promoter 
(Neidhart et al., 2000). A single unmethylated CpG in a promoter of IL-6 in 
monocytes was also reported rendering the expression of IL-6 more inducible by LPS 
stimulation (Nile et al., 2008). On the contrary, the CpG island in the promoter of 
death receptor 3 (DR3), a member of the apoptosis-inducing Fas gene family, was 
shown to be specifically methylated in first or second passage RA synovial cells and 
the expression of DR3 was accordingly downregulated (Takami et al., 2006). The 
authors concluded that the downregulation of DR-3 could be responsible for the 
resistance to apoptosis in these cells. This finding resembles certain aspects 
observed in malignant cells where methylation of specific promoters, for example in 
tumor suppressor genes, is observed. 
 
3.2. Histone acetylation in RA 
Acetylation of histones H3 and H4 in the nucleosomes of gene promoters is related to 
the activation of gene expression (Grunstein, 1990; Struhl, 1998). This fact is thought 
to be due to the binding of an acetyl group to a lysine residue in histones that 
abolishes the positive charge on the lysine and thus loosens the tight interaction 
between the positively charged histone octamer and negatively charged DNA. 
Therefore, the DNA becomes accessible for the transcription machinery. The status 
of histone acetylation depends on the activity of histone acetyltransferases (HATs) 
and histone deacetylases (HDACs) (Ito and Adcock, 2002). It has been described by 
Huber et al in our laboratory that in RA synovial tissue the balance of HAT/HDAC 
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activity is strongly shifted towards histone acetylation (Huber et al., 2007). 
Specifically, we could show a downregulation of HDAC1 and 2 in the synovium of 
patients with RA. However, isolated RASF do not have a changed expression of 
HDAC1 and 2 compared to OASF (Hemmatazad et al., 2008). 
In other studies, it has been observed that the HDAC inhibitor FK228 in vivo inhibits 
joint swelling, synovial inflammation and joint destruction in mice through the 
induction of p16INK4a and the upregulation of p21(WAF1/Cip1) (Nishida et al., 
2004).  Furthermore, FK228 was recently described to suppress the production of 
VEGF in vivo and to block angiogenesis in synovial tissue in collagen-antibody-
induced arthritis (Manabe et al., 2008). Another HDAC inhibitor, Trichostatin A (TSA), 
was shown to induce cell cycle arrest and apoptosis in RASF and being particularly 
effective in combination with ultrasound treatment (Nakamura et al., 2008). TSA was 
also demonstrated to sensitise RASF to TRAIL-induced apoptosis, however in this 
study TSA had no effect on apoptosis when used in the absence of TRAIL (Jungel et 
al., 2006). In conclusion, on one hand there is a significant downregulation of single 
HDACs, on the other hand inhibitors of HDACs ameliorate the disease in animal 
models. These reports suggest that HDACs might be less active in RA and/or 
misplaced in the subcellular compartments, for example being localised aberrantly to 
specific promoter sites, and thereby contributing further to the pathogenesis of RA. 
However, it needs to be also taken into account that HDACs have in addition non-
histone proteins for substrates. Therefore, it might be considered whether inhibition 
or rather redirection to a proper localization of HDACs is feasible for the treatment of 
RA (Maciejewska et al., 2008). 
 
3.3. MicroRNA in RA 
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MicroRNAs (miRNA) are a recently recognized class of modulators of gene 
expression. MicroRNA are small non-coding single-stranded RNA molecules that 
downregulate gene expression on the posttranscriptional level. The expression 
pattern of miRNA has been suggested to be altered in RA. Indeed, expression of 
miR-155 and miR-146a was found to be higher in RASF than in OASF (Nakasa et al., 
2008; Stanczyk et al., 2008b). Moreover, the expression of miR-155 was further 
enhanced by TNFα, IL-1β and the ligands of TLR2, 3 and 4 (Stanczyk et al., 2008b). 
Interestingly, the expression of miR-155 in RASFs had a repressive effect on the 
expression of MMP-1 and MMP-3, suggesting an induction of counter regulatory 
mechanisms in the circle of inflammation and destruction. However, in another study 
it has been proposed that miR-146a, even though expressed at higher levels in RA, 
is not able to perform its function as a negative regulator for the expression of TRAF6 
and IRAK-1, two molecules involved into the pathway of TNFα synthesis (Pauley et 
al., 2008). Most interestingly, microparticles, which are small vesicles released from 
activated or dying cells and present abundantly in the synovial fluid of patients with 
RA, also contain miRNA (Jungel et al., 2007; Stanczyk et al., 2008a). These 
observations support the notion that microparticles are intra-cellular mediators of 
inflammation and entail the activation of synovial cells even more interesting (Distler 
et al., 2005).  
 
In summary, accumulating data suggest that the intrinsic activation of RASF could be 
a result of epigenetic modulation (Karouzakis et al., 2006). We hope that the 
increasing knowledge in the new field of epigenetics has a great potential for 




Even though there has been recently accumulating evidence for the involvement of 
the innate immune system into the development of synovitis (Ospelt and Gay, 
2008b), adaptive immunity has long been known to play a critical role in the 
pathogenesis of RA. In autoimmune disorders, such as RA, the cells of the adaptive 
immunity recognize self antigens and propagate a self directed autoimmune reaction. 
Numerous studies have shown that self reactive T cells release proinflammatory 
cytokines and promote the production of immunoglobulins directed to self antigens by 
B cells (Halldorsdottir et al., 2000; Kurki et al., 1992; Silman et al., 1992). In this 
regard, B cell depletion therapy improves RA significantly, whereas targeting the CD4 
molecule on T cells did not show to be beneficial in clinical trials (Perosa et al., 2005; 
Schulze-Koops and Lipsky, 2000). A remarkable specificity of 98% for RA 
characterises the antibodies directed to citrullinated peptides (anti-CCP) (Jansen et 
al., 2002; Mathsson et al., 2008; Schellekens et al., 2000). Among the antigens 
recognized by anti-CCP antibodies are citrullinated fibrin and vimentin (Mathsson et 
al., 2008). Anti-CCPs are present very early in the disease, predict radiographic 
progression and are associated with HLA-DRB1 (de Vries-Bouwstra et al., 2008; 
Innala et al., 2008; Liao et al., 2008). Although the presence of rheumatoid factors 
together with anti-CCP show the best predictive value for the development of RA, 
especially in smokers (Goeb et al., 2008; Klareskog et al., 2006), anti-CCP are not 
yet included in the ACR criteria. Auto-antibodies reactive with type II collagen (CII), 
vimentin, decorin, enolase and aldolase A have been described in RA (Kinloch et al., 
2005; Mathsson et al., 2008; Polgar et al., 2003; Ukaji et al., 1999). Most recently we 
have engaged the SEREX technique to identify novel auto-antibodies in RA (Al-
Shamisi et al., 2005; Maciejewska et al., 2007). The SEREX technique is a valuable 
screening method that allows for a fast identification of all cDNA encoded proteins 
from a tissue that are recognized by autologous sera. The main advantage of the 
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SEREX over classical methods such as Western blot is the possibility for the 
identification of a broad spectrum of auto-antibodies reactive with proteins expressed 
extra- and intra- cellularly since it engages screening of a complete gene expression 
library. Using the SEREX technique we found increased levels of auto-antibodies to 
serpin E2 in synovial fluids and sera from patients with RA (Maciejewska et al., 
2007). Serpin E2 is a natural inhibitor of the plasmin system involved into the 
activation of more pathogenic enzymes (Mansilla et al., 2008). Interestingly, anti-
serpin E2 auto-antibodies interfered with the inhibitory activity of serpin E2. To our 
knowledge, this is the first reported functionally active auto-antibody in RA that might 
contribute to the pathogenesis of the disease. 
 
The data reviewed here suggest a strong interplay between the innate and adaptive 
immune response in RA. However, it is a great future challenge to study the 
interactions between the two intertwined immune systems and to elucidate the 
multiple epigenetic modulations of all cells contributing to innate and adaptive 
immunity and joint destruction in RA (Figure 2). 
 
Figure 1. Epigenetic modulations of the chromatin. The global hypomethylation of 
the DNA in RA leads to an increase in gene expression. Hyperacetylation of histones 
in specific promoter sites renders the DNA region accessible for the transcrption 
machinery. MicroRNA encoded by the DNA silences specific genes in a 
posttranscriptional manner. Other modifications of histones are indicated, such as 
sumoylation, ubiquitination, methylation and phosphorylation.  Methylated cytosine in 
DNA is shown as filled and nonmethylated as open circles. The modifications of 
histone tails are indicated as follows: SUMO – sumoylation, Ub – ubiquitination, Ac – 
acetylation, P – phosphorylation, Me – methylation. 
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 Figure 2. Epigenetic modifications in RA investigated in the World Health 
Organization Collaborating Center for Molecular Biology and Novel Therapeutic 
Strategies for Rheumatic Diseases, University Hospital Zurich. 
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